De marca
Eryc ya no se vende con receta.
Nombre genérico: erythromycin
Se usa para: Infecciones respiratorias · Infecciones de la piel · Infecciones de transmisión sexual · Tos ferina (pertussis) · Prevenir la fiebre reumática · Enfermedad del legionario · Infección intestinal por amebas (amebiasis) · Difteria · 7 más
Pregunte el precio sin seguro
Genérico autorizado
El mismo Eryc, sin el nombre de marca. Por lo general, cuesta menos que Eryc.
La FDA aprobó uno en esta forma, pero todavía no está en las farmacias. Se venden otras formas o concentraciones, pero cambiar a una necesitaría una receta nueva.
Eryc ya no se vende con receta.
El mismo medicamento que Eryc, sin el nombre de marca
El mismo medicamento que Eryc, sin el nombre de marca. Su NDC es el número que identifica el producto exacto: déselo a la farmacia para que lo busquen o lo pidan.
erythromycin
Dele este NDC a la farmacia
Qué decir en la farmacia
“Antes de surtir mi Eryc, ¿me puede decir cuánto pagaría por el medicamento de marca y por el genérico autorizado de Dr. Reddy's Laboratories (NDC 75907-076-01)?”
¿Paga sin seguro? Pregunte el precio sin seguro de cada uno. Si tiene seguro, pregunte cuánto le cobra su plan por cada uno.
Fuente: FDA, actualizado el 16 de noviembre de 2026
Etiquetas oficiales y listas de ingredientes de DailyMed (Biblioteca Nacional de Medicina de EE. UU.). Los ingredientes aparecen en inglés, como en la etiqueta.
Eryc ya no se vende, así que no hay una etiqueta de marca actual para comparar. Esta es la etiqueta del genérico autorizado.
Activo: erythromycin 250 mg
Inactivos:
La FDA aprobó uno en esta forma, pero todavía no está en las farmacias. Se venden otras formas o concentraciones, pero cambiar a una necesitaría una receta nueva.
Erythromycin is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below:
Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved) (see appropriate sulfonamide labeling for prescribing information).
Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes.
Listeriosis caused by Listeria monocytogenes.
Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals.
Respiratory tract infections due to Mycoplasma pneumoniae.
Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment).
Diphtheria: Infections due to Corynebacterium diphtheriae, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers.
Erythrasma: In the treatment of infections due to Corynebacterium minutissimum.
Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy.
Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents.
Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: Erythromycin lactobionate for injection, USP followed by erythromycin base orally, as an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months.
Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis.
When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum.
Legionnaires' Disease caused by Legionella pneumophila. Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease.
Prophylaxis
Prevention of Initial Attacks of Rheumatic Fever
Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients.1 The therapeutic dose should be administered for ten days.
Prevention of Recurrent Attacks of Rheumatic Fever
Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever).1
To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin delayed-release capsules, USP and other antibacterial drugs, erythromycin delayed-release capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Fuente: la etiqueta de la FDA de erythromycin (Dr. Reddy's Labratories Inc.), 25 de septiembre de 2025. Etiqueta completa en DailyMed
Los precios cambian: confírmelos con la farmacia antes de surtir su receta. drugalt.com/es/drug/eryc/